Análisis Argos
FRO
FROSin veredicto
Frontline Plc · Industrials
US$ 36.75
precio al 2026-07-04
Valor justo Argos*
US$ 42
vs. su valor justo
+14%
Score Argos
56/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Cotiza 14% por debajo de su valor justo.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
VALOR4/6FUTURO2/6PASADO4/6SALUD2/6DIVIDENDO3/6
El Iris de calidad
VALOR4/6FUTURO2/6PASADO4/6SALUD2/6DIVIDENDO3/6
ValorCotiza por debajo de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance razonable
DividendoRetorno al accionista moderado
Score Argos56de 100Sin veredicto
Ingresos4%
US$ 2 B
Margen operativo21%
30.2%
Flujo de caja libre472%
US$ 0.7 B
Deuda neta
US$ 2.8 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 8.2B
P/E21.6x
EV/EBITDA11.9x
FCF yield8.2%
ROIC11%
Margen operativo30.2%
Crecim. ingresos-4.2%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

businesswire.com · 30 jun
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibito.
globenewswire.com · 25 jun
Mister Car Wash Directs Frontline Engagement to New Heights with Staffbase, Achieving 93% Active User Adoption Across 550+ Locations
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Mister Car Wash , one of the largest car wash companies in the United States, has successfully transformed its frontline employee experience by partnering with Staffbase , a leading provider of employee communication platforms. Through the launch of its branded app, Mister Connect, the company has established a single source of truth for its 7,000+ employees across more than 550 locations in 23 states.
benzinga.com · 18 jun
Oil Is Heading For Its Worst Week In Months. Why Are Tanker Stocks Still Rising?
The Middle East trade may be entering a new phase. Oil prices have retreated sharply this week as signs of progress in U.S.-Iran talks eased some fears of a broader regional disruption.
globenewswire.com · 17 jun
SPARC AI Strengthens Ukraine Market Entry, Engages CFC Defence to Drive Frontline Adoption of Overwatch and Expand Its Roster of Partnered Drone Manufacturers
SPARC AI engages Ukraine-based CFC Defence to lead its market-entry programme for Overwatch, accelerating drone OEM partnerships and frontline adoption.
benzinga.com · 12 jun
Trump's Hormuz Warning Could Be A Surprise Catalyst For Tanker Stocks
A Truth Social post from President Donald Trump may have handed tanker investors a new storyline.
benzinga.com · 12 jun
Crude Oil Slips Below $90—Yet These 4 Tanker Stocks Reach Top-Tier Momentum Zones
While global crude prices have retreated beneath the critical $90 per barrel support level, the underlying shipping market is telling a different story as four major oil tanker stocks simultaneously surge into top-tier momentum zones.
globenewswire.com · 11 jun
Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company's global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL.
gurufocus.com · 9 jun
Is Frontline PLC (FRO) Overvalued After 3.6% Rally? GF Value Says Overvalued
On June 09, 2026, Frontline PLC (FRO) shares rose 3.6%, bringing the current price to $36.27. This increase comes amid a 52-week range that saw the stock hit a

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.